Heron Therapeutics Inc. (HRTX)
HRTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/818033/000119312526073515/0001193125-26-073515-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | HRTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000818033 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $154.9M |
| Net income | -$20.2M |
| Operating income | -$2.5M |
| Net margin | -13.0% |
| Operating margin | -1.6% |
| Revenue growth | +7.4% |
| Cash | $28.6M |
| Total assets | $255.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Liquidity and Going Concern In accordance with Accounting Standards Update ("ASU") No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40) , we have evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern for a period of at least one year from the date of iss" | 10-Q 2026-11-09 |
| Cash and burn | $11.6M cash; operating cash flow -$3.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 190,273,587 (2026-11-04); 183,362,522 a year earlier; 150,072,640 three years earlier. | Cover page 2026-11-04 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-06-25 |
| Auditor | WithumSmith+Brown, PC, Orlando, Florida, United States | PCAOB Form AP 2026-03-05 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $35.3M | -$5.0M | -$794K | $11.6M | No debt tags | $148.2M | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $37.7M | -$5.5M | -$2.2M | $20.7M | No debt tags | $151.2M | 10-Q 2026-08-10 |
| Q1 2026 2026-03-31 | $34.7M | -$8.1M | -$1.5M | $26.1M | No debt tags | $150.7M | 10-Q 2026-05-11 |
| Q4 2025 2025-12-31 | $40.6M | -$3.0M | -$9.2M | $28.6M | No debt tags | $154.9M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $38.2M | -$17.5M | $1.3M | $43.1M | No debt tags | $155.1M | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $37.2M | -$2.4M | -$10.9M | $16.5M | $149.8M | $149.7M | 10-Q 2026-08-10 |
| Q1 2025 2025-03-31 | $38.9M | $2.6M | -$8.9M | $19.3M | No debt tags | $148.5M | 10-Q 2026-05-11 |
| Q4 2024 2024-12-31 | $40.8M | $3.7M | -$11.8M | $25.8M | No debt tags | $144.3M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2025-09-09 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-11-09 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +6.9% |
| 1 month | -20.5% |
| 3 months | -6.1% |
| Year to date | -76.2% |
| 1 year | -72.1% |
| From 52-week high | -79.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| XLO | Xilio Therapeutics Inc. | $7.70 | -3.08% | $54.4M |
| AZR | Azora Therapeutics Inc. | $3.81 | -6.85% | $54.4M |
| INCR | Intercure Ltd. | $3.63 | -4.22% | $54.5M |
| CING | Cingulate Inc. | $3.75 | -12.79% | $54.5M |
| VRCA | Verrica Pharmaceuticals Inc. | $3.20 | -10.11% | $55.0M |
| SPRO | Spero Therapeutics Inc. | $0.9464 | -5.35% | $55.1M |
| CLNN | Clene Inc. | $3.66 | -6.63% | $52.7M |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $2.88 | -4.32% | $56.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier